Non-GCB/ABC Diffuse Large B-Cell Lymphoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Non-GCB/ABC Diffuse Large B-Cell Lymphoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1

NCT06667687

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the B…

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to…

United States165 participantsStarted 2025-01-16

Treatment: ABBV-291

All recent trials (6 shown)

TerminatedPhase 2

NCT05319028

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Study CX-659-401 is a multicenter, open-label, phase 2 study of mivavotinib to evaluate the single-agent activity of mivavotinib in patients with relapsed/refra…

United States2 participantsStarted 2022-06-23

Treatment: Mivavotinib

UnknownPhase 2

NCT04835870

Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Aim of this study will evaluate the efficacy and safety of zanubrutinib in combination with R-CHOP for newly diagnosed untreated Non-GCB DLBCL Patients

China78 participantsStarted 2021-04-01

Treatment: Zanubrutinib, Rituximab

Non-GCB/ABC Diffuse Large B-Cell Lymphoma

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the B…

All recent trials (6 shown)

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the B…

All recent trials (6 shown)

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies